Insulet (PODD) Tops Q2 EPS by 9c, Lifts Revenue Guidance

Insulet (NASDAQ: PODD) reported Q2 EPS of ($0.08), $0.09 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $87.3 million versus the consensus estimate of $81.1 million.

GUIDANCE:

Insulet sees Q3 2016 revenue of $88-91 million, versus the consensus of $87 million.

Insulet sees FY2016 revenue of $345-355 million, versus the consensus of $343.6 million.

For earnings history and earnings-related data on Insulet (PODD) click here.

You May Also Be Interested In

• Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Offic
• Femasys Inc. (FEMY) Misses Q2 EPS by 20c
• Seritage Growth Properties (SRG) Reports Q2 Loss of $0.13